Melatonin is the highest-risk product in the gummy category, and not because the molecule is dangerous. It is risky because the regulatory status changes at every border, the dose sold is usually ten to thirty times the physiological dose, the ingredient is one of the least reliably labelled in the supplement market, and the format is a sweet that children can eat by the handful.
This guide is the manufacturing and compliance view: physiological versus sold dose, the country-by-country patchwork, content variability evidence, stability in a gummy matrix, analytical testing, child-resistant packaging, cost build and the claims that survive review.
Dose: physiological versus what is sold
| Dose | Context | Effect | Regulatory status (typical) |
|---|---|---|---|
| 0.1–0.3 mg | Endogenous night-time plasma level | Replacement physiology | Below most supplement doses |
| 0.3–1 mg | Physiological / circadian studies | Sleep-onset signalling, phase shifting | Sold as a supplement in the US; prescription-only in much of the EU |
| 1–3 mg | Common European OTC and paediatric doses | Sleep latency reduction | Restricted in many markets |
| 3–5 mg | Standard US supplement dose | Modest additional benefit over 1 mg | Supplement in the US and Canada |
| 5–10 mg | High-dose commercial products | No clear advantage; more next-day grogginess | Permitted in some markets, restricted in others |
| >10 mg | Research / clinical only | Supraphysiological | Not appropriate for a consumer gummy |
The dose-response literature is consistent on one point: the difference between 0.3 mg and 3 mg is meaningful, and the difference between 3 mg and 10 mg is largely not. A 10 mg gummy sells because the number looks stronger, not because it works better.
The regulatory patchwork
| Market | Status of melatonin | Practical consequence |
|---|---|---|
| United States | Dietary supplement | Can sell as a gummy; structure/function claims with disclaimer |
| Canada | Natural health product, monograph dose limits | NPN required before sale; dose and duration limits apply |
| European Union | Not authorised as a food supplement; medicinal in most member states | Cannot be sold as a food supplement in most of the EU |
| United Kingdom | Prescription-only medicine | Not a consumer supplement |
| Australia / New Zealand | Listed medicine or restricted schedule | AUST L number; specific pack warnings |
| Japan | Not permitted in foods; drug category | Not a gummy ingredient |
| China | Health food / drug pathway | Long registration; not a standard supplement ingredient |
This single table explains why so many melatonin gummies are US-only products with a compliance disclaimer, and why a European brand cannot simply copy a US formula. If you plan to sell in the EU or UK, melatonin is not the ingredient to build a launch around.
Content: the evidence that should shape your QC
| Finding | Study | Manufacturing implication |
|---|---|---|
| Melatonin content deviated from the label by more than 10 % in a substantial share of products tested | Erland & Saxena, J Clin Sleep Med 2017 (PMID 27855744) | Test every finished batch; do not rely on input weight |
| Serotonin was detected in a quarter of the products analysed | Same study | Raw-material COA must include serotonin as a contaminant |
| Label accuracy varies by product type (tablets, capsules, gummies) | Same study | Gummy matrix is harder to assay; method validation matters |
The serotonin finding is the one that changes sourcing. Melatonin is often extracted from animal pineal tissue or synthesised; either route can carry serotonin as a process impurity. Ask for a certificate of analysis with a serotonin limit, and test for it on the finished product at least once per supplier change.
Stability in a gummy matrix
| Stress | Effect on melatonin | Loss over 12 months | Control |
|---|---|---|---|
| Heat during depositing (90–100 °C) | Some degradation, mostly tolerable | 2–8 % process loss | Add late, minimise hold time |
| Light exposure | Photodegradation | 10–30 % if transparent packaging | Opaque jar, amber or white HDPE |
| Oxidation | Indole ring oxidation | 5–15 % | Antioxidant, low headspace oxygen |
| Water activity above 0.65 | Hydrolysis and microbial risk | Accelerated loss | Cure to aw ≤0.60 |
| Interaction with reducing sugars | Browning, matrix binding | Variable | Non-reducing syrup where possible |
Melatonin is more robust than vitamin C but far less robust than vitamin D. Plan on 15–25 % overage for an 18-month claim, and confirm it with your own accelerated data rather than a supplier's general statement.
Assay: what to demand
| Test | Method | Why | Typical cost |
|---|---|---|---|
| Melatonin assay | LC-MS/MS or HPLC-UV | Confirms dose in the finished matrix | $120–300 |
| Serotonin impurity | LC-MS/MS | Contaminant from extraction or synthesis | $150–350 |
| Content uniformity | Per-piece assay, 10 units | Gummies vary piece to piece | $200–450 |
| Dissolution / release | USP <711> adapted | Chewable matrix, not a tablet | $250–500 |
| Microbiology | Standard panel | Gummy aw is a microbial risk | $80–200 |
Content uniformity is the test brands skip and should not. A 5 mg claim with pieces ranging from 3.5 to 6.5 mg is a dosing problem, and gummies made on a volumetric depositor routinely show more variation than tablets.
Taste and child safety
| Issue | Cause | Mitigation |
|---|---|---|
| Bitter, medicinal note | Melatonin itself | Masking flavour, acid balance, low dose per piece |
| Sweet, candy-like profile | Sugar + fruit flavour | Deliberate: but conflicts with child-safety messaging |
| Accidental paediatric ingestion | Looks like sweets, sold in large bottles | Child-resistant closure, smaller count, bittering agent |
| Next-day grogginess | Dose above need | Lower dose per piece; two-piece serving with 1 mg each |
Paediatric melatonin ingestions reported to poison centres rose sharply after gummies became the dominant format. If you are making a melatonin gummy, child-resistant packaging is not a marketing differentiator — it is the minimum responsible specification, and several retailers now require it.
Sourcing melatonin: synthetic, extract, and what the COA should say
| Source | Purity | Cost | Impurity risk | Buying note |
|---|---|---|---|---|
| Synthetic (chemical synthesis) | 99 %+ typical | Low | Residual solvents, synthesis by-products | Most common; ask for residual solvent data |
| Animal pineal extract | Variable | High | Serotonin, tissue-derived contaminants | Almost never appropriate for a consumer gummy |
| Microbial / fermentation | 98–99 % | Medium | Fermentation residues | Useful for “non-animal” positioning |
| Plant-derived (trace levels) | Very low content | Not viable | — | Marketing only; no commercial supply at dose |
A usable melatonin COA contains: assay by a named method, serotonin limit, residual solvents, heavy metals, microbial limits, and a lot number that traces to the drum. Anything less and you are buying a number, not an ingredient.
A worked formula: 2 mg per piece, 2.5 g gummy
| Ingredient | % of batch | Per piece | Function |
|---|---|---|---|
| Glucose syrup (DE 42) | 38.0 % | 950 mg | Body, aw control |
| Sucrose | 28.0 % | 700 mg | Sweetness, texture |
| Water | 18.0 % | 450 mg | Processing, driven off in curing |
| Gelatin (200 Bloom) | 7.0 % | 175 mg | Gel structure |
| Melatonin (with 20 % overage) | 0.096 % | 2.4 mg | Active |
| Citric acid | 1.2 % | 30 mg | Flavour balance, masking |
| Natural flavour (berry) | 0.40 % | 10 mg | Masking the bitter note |
| Fruit concentrate colour | 0.30 % | 7.5 mg | Appearance |
| Carnauba / oil polish | 0.05 % | 1.3 mg | Anti-stick |
At 2 mg per piece, a two-piece serving is 4 mg — a normal commercial dose — and the bitter note is manageable with a berry flavour and a citric acid balance. Pushing to 5 mg per piece triples the masking problem and doubles the number of pieces a child could eat before reaching a problematic dose, which is the argument against high-dose gummies that nobody puts on the marketing page.
Release protocol for a melatonin batch
| Checkpoint | Specification | Frequency |
|---|---|---|
| Raw material identity and assay | ≥99 % with serotonin limit | Every lot |
| Syrup temperature at melatonin addition | ≤85 °C | Every batch, logged |
| Piece weight | 2.5 g ±5 % | Every 15 min |
| Water activity at release | ≤0.60 | Every batch |
| Finished assay and uniformity | 90–110 % of label, RSD <6 % | Every batch |
| Serotonin | Below the agreed limit | Every batch, or per supplier change with a risk review |
| Seal integrity and closure torque | No leakers; CR closure functional | Every batch |
| Stability pull | 0, 3, 6, 12, 18, 24 months | Scheduled |
The single most useful control in this table is the addition temperature. Melatonin is added late, below 85 °C, and logged — because a batch that goes in at 100 °C and holds for twenty minutes loses potency in a way that only shows up in the finished assay three days later.
Cost build
| Line item | 3 mg gummy, 2.5 g piece | Notes |
|---|---|---|
| Melatonin (with overage) | $0.006 | Cheap ingredient; the risk is QC, not cost |
| Base, sweetener, flavour | $0.022 | Masking is where the money goes |
| Depositing and curing | $0.014 | Standard gummy line |
| Assay and uniformity testing | $0.009 | Amortised over the batch |
| Child-resistant jar and label | $0.032 | More than a standard jar |
| Ex-works per unit | $0.083 | 60-count bottle ≈ $4.98 |
Two-thirds of the cost sits outside the active. That is why cutting corners on testing or packaging is the classic false economy in this category: the ingredient is pennies, the liability is not.
Failure modes
- Label inaccurate by 20 %. No finished-product assay, only input weighing.
- Serotonin contamination. Raw material sourced without an impurity specification.
- Pieces fuse in the bottle. aw above 0.65 or insufficient polishing.
- Potency drop at 12 months. Transparent jar plus no overage.
- Retail rejection. No child-resistant closure, or a dose above the market monograph limit.
- Customs seizure in the EU. Melatonin treated as an unauthorised medicinal product.
If you are weighing formats before you choose a supplier, our pages on sleep supplement manufacturing and gummy production set out the equipment, testing and minimum volumes behind each one. For the next decision in the sequence, read the gummy OEM process step by step.
Frequently asked questions
Is melatonin allowed in gummies?
In the United States and Canada, yes, as a supplement or natural health product. In most of the EU and the UK it is a medicine, so a food-supplement gummy is not a lawful product there.
What dose should a gummy contain?
The lowest dose that supports the claim. 1–3 mg per serving is defensible; 10 mg is a marketing number with more downside than benefit.
Why do melatonin products vary so much?
Weak finished-product testing, raw-material variability and a matrix that is hard to assay. The 2017 J Clin Sleep Med analysis found substantial label deviations and serotonin contamination across products.
Does melatonin survive gummy manufacturing?
Yes, with 2–8 % process loss and 10–30 % loss over a year if packaging is transparent. Overage plus an opaque jar closes most of the gap.
Do I need child-resistant packaging?
Not legally in every market, but it is the responsible specification and increasingly a retailer requirement. Paediatric ingestions of melatonin gummies have risen sharply.
Can I combine melatonin with other sleep ingredients?
Yes — magnesium, L-theanine, glycine and botanicals are common. Watch total actives per piece and check each one's regulatory status in the target market.
How do I test for serotonin contamination?
LC-MS/MS on the raw material and on the finished product after any supplier change. Ask for a specification limit, not a “not detected” statement without a method.
What shelf life can I claim?
18–24 months is achievable with an opaque jar and measured overage. Without stability data, 12 months is the honest answer.
Sources and further reading
Regulatory and standards
- US FDA, dietary supplements; 21 CFR Part 111.
- Health Canada, NHP monographs — melatonin dose and labelling limits.
- EU: melatonin is not listed as an authorised food supplement ingredient; national medicines agencies govern it. See EMA and Directive 2002/46/EC.
Peer-reviewed research
- Erland LAE, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13:275–281. PMID 27855744.
- Efficacy of melatonin for chronic insomnia: systematic reviews and meta-analyses. Sleep Med Rev. 2022. PMID 36179487 — effect sizes by dose and population.
- Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013. PMID 23691095 — the sleep-latency evidence base.
- Circadian rhythm dysregulation and restoration: the role of melatonin. Nutrients. 2021. PMID 34684482 — why timing matters more than dose.
- Efficacy and safety of supplemental melatonin for delayed sleep-wake phase disorder in children: an overview. Sleep Med X. 2020. PMID 33870175 — paediatric dosing and safety.
Standards and industry references
- ISO 22000; GFSI; US FDA HACCP principles.
- United States Pharmacopeia, general chapters <711>, <905>, <2021>.
Regulatory status summarised as of 2026 for planning purposes only; confirm current national rules before manufacture or import, as melatonin classification changes between jurisdictions and over time.
